
Ilaprazole sodium
CAS No. 172152-50-0
Ilaprazole sodium( —— )
Catalog No. M12619 CAS No. 172152-50-0
Ilaprazole is a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 40 | In Stock |
![]() ![]() |
5MG | 63 | In Stock |
![]() ![]() |
10MG | 84 | In Stock |
![]() ![]() |
25MG | 178 | In Stock |
![]() ![]() |
50MG | 290 | In Stock |
![]() ![]() |
100MG | 462 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameIlaprazole sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionIlaprazole is a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.
-
DescriptionIlaprazole is a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity. A weak base, ilaprazole accumulates in the acidic environment of the secretory canaliculus of the gastric parietal cell where it is converted to an active sulfenamide form that binds to cysteine sulfhydryl groups on the luminal aspect of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production.(In Vitro):On cumulation of 14C-aminopyrine in histamine stimulated parietal cells, the IC50 of Ilaprazole (IY-81149) sodium is 9 nM.(In Vivo):Ilaprazole sodium (3-30 mg/kg; i.d.) dose-dependently inhibits gastric acid secretion.In anesthetized rats, Ilaprazole sodium dose-dependently increases gastric pH which is lowered by histamine infusion. In the case of i.v. injection, the ED50 of Ilaprazole sodium and Omeprazole is 1.2 and 1.4 mg/kg and in the case of i.d. administration, the ED50 of Ilaprazole sodium and omeprazole is 3.9 and 4.1 mg/kg, respectively. Ilaprazole sodium also significantly inhibits pentagastrin-stimulated gastric secretion. Its ED50 is 2.1 mg/kg and that of Omeprazole was 3.5 mg/kg with i.d. administration. In the case of i.v. injection, Ilaprazole sodium is equipotent to Omeprazole. Ilaprazole sodium also inhibits gastric acid secretion strongly in fistular rats. The ED50 of Ilaprazole sodium administered intraduodenally is 0.43 mg/kg and that of omeprazole Is 0.68 mg/kg.
-
In Vitro——
-
In VivoAnimal Model:Male SD rat (after pylorus ligation) Dosage:3, 10, 30 mg/kg Administration:Intraduodenally Result:The acid output and volume significantly inhibited by about 60 % and 46 % at 3 mg/kg were s, respectively. At 30 mg/kg, it showed 93 % and 73 % inhibition on acid output and volume, respectively.
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetProton Pump
-
RecptorProton pump
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number172152-50-0
-
Formula Weight388.44
-
Molecular FormulaC19H17N4O2SNa
-
Purity>98% (HPLC)
-
SolubilitySoluble in DMSO
-
SMILES[Na+].CC1=C(C=CN=C1CS(=O)C2=NC3=C([N-]2)C=C(C=C3)N4C=CC=C4)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Seo KA, et al. Xenobiotica. 2012 Mar;42(3):278-84.
molnova catalog



related products
-
Capmatinib 2HCl
INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.
-
Saviprazole
Saviprazole (Hoe-731), a proton pump inhibitor, is used potentially for treatment of gastric ulcer.
-
Revaprazan
Revaprazan (SB-641257;YH-1885) is a potent potassium-competitive acid blocker (P-CAB) that inhibits H+,K+-ATPase in a reversible and K+-competitive manner.